Physician profile
John C Allen
NPI 1417275652
$21,174.92
in general payments reported to CMS, 2019-2025
71 companies · $3,480 in 2025
The $3,480 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,422 · 2020: $1,549 · 2021: $2,415 · 2022: $2,994 · 2023: $4,734 · 2024: $3,581 · 2025: $3,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,652.26 |
| Education | $142.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,779.89 | 2019-2025 | |
| Exelixis INC. | $1,721.58 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $1,347.66 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,184.92 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $1,107.52 | 2019-2025 | |
| Janssen Biotech, INC. | $1,093.93 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $1,077.62 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Amgen INC. | $845.86 | 2019-2023 | Blincyto, Vectibix, Xgeva |
| Gilead Sciences, INC. | $806.49 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $729.23 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
| Celgene Corporation | $669.08 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Lilly USA, LLC | $630.38 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $608.75 | 2019-2025 | Tecentriq, Polivy, Itovebi |
| Astellas Pharma US INC | $597.55 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Abbvie INC. | $578.64 | 2019-2025 | Venclexta |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $569.07 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $500.63 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Seagen INC. | $425.66 | 2019-2023 | Padcev, Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $380.40 | 2019-2023 | Imbruvica |
| Eisai INC. | $372.94 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $284.83 | 2019-2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $237.47 | 2019-2025 | |
| Beigene USA, INC. | $226.17 | 2020-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $219.04 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $215.11 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genzyme Corporation | $209.87 | 2019-2025 | |
| Tersera Therapeutics LLC | $194.40 | 2020-2025 | Zoladex, Xermelo |
| Aveo Pharmaceuticals, INC. | $175.76 | 2021-2025 | Fotivda |
| Daiichi Sankyo INC. | $171.42 | 2020-2024 | Injectafer |
| Pharmacosmos Therapeutics INC. | $139.69 | 2022-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $134.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $124.29 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $114.71 | 2019-2025 | Provenge |
| Puma Biotechnology, INC. | $114.42 | 2019-2023 | |
| Array Biopharma INC | $110.18 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Amag Pharmaceuticals, INC. | $105.57 | 2019-2022 | |
| G1 Therapeutics, INC. | $91.01 | 2022-2023 | Cosela |
| Beone Medicines USA, INC. | $90.67 | 2025 | Brukinsa, Tevimbra |
| Mirati Therapeutics, INC. | $90.26 | 2023-2024 | Krazati |
| Coherus Oncology, INC. | $88.09 | 2021-2024 | |
| Emd Serono, INC. | $85.09 | 2020-2023 | Tepmetko |
| Adaptive Biotechnologies Corporation | $70.22 | 2023-2024 | Clonoseq |
| Tempus Ai, INC | $63.45 | 2024 | |
| Sobi, INC | $58.32 | 2023-2024 | |
| Secura Bio, INC. | $55.46 | 2020-2022 | |
| Taiho Oncology, INC. | $53.40 | 2019-2021 | |
| Acceleron Pharma, INC. | $45.61 | 2020-2021 | |
| Tesaro, INC. | $41.34 | 2019 | |
| Kyowa Kirin, INC. | $40.99 | 2023-2025 | Poteligeo |
| Blueprint Medicines Corporation | $40.85 | 2021 | |
| Kite Pharma, INC. | $38.05 | 2022-2023 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.92 | 2025 | |
| Foundation Medicine, INC. | $30.31 | 2020 | |
| Agios Pharmaceuticals, INC. | $28.86 | 2019-2023 | Pyrukynd |
| Clovis Oncology, INC. | $26.46 | 2020 | |
| Deciphera Pharmaceuticals INC. | $25.23 | 2025 | Qinlock, Tgct |
| Springworks Therapeutics, INC. | $24.43 | 2025 | Ogsiveo |
| Stemline Therapeutics INC. | $23.12 | 2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $23.09 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $22.74 | 2025 | Sylvant |
| Legend Biotech USA INC. | $20.84 | 2025 | Carvykti |
| Dova Pharmaceuticals | $19.65 | 2021 | |
| Genmab U.S., INC. | $19.35 | 2024 | Epkinly |
| Adc Therapeutics America, INC. | $19.27 | 2024 | |
| Servier Pharmaceuticals LLC | $18.25 | 2024 | |
| Novo Nordisk INC | $17.64 | 2025 | Wegovy, Saxenda |
| Verastem, INC. | $14.65 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.33 | 2019 | |
| Emmaus Medical, INC. | $13.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.32 | 2019 | |
| Blue Earth Diagnostics | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.